Trial
NCT00848601
Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Astex Pharmaceuticals, Inc.
Collaborators
—
Condition
Prostate Cancer
Intervention
SGI-1776
Why stopped
The dose limiting toxicity of cardiac QTc prolongation was identifiedin the phase 1 study in patients with refractory prostate and lymphoma
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-02